Nivolumab-refractory patients with advanced non-small-cell lung cancer

被引：15

作者：

Costantini, A. ^{[1
,2
]}

Fallet, V. ^{[1
,2
]}

Corny, J. ^{[3
]}

Friard, S. ^{[4
]}

Chouaid, C. ^{[5
]}

Duchemann, B. ^{[6
]}

Giroux-Leprieur, E. ^{[7
]}

Taillade, L. ^{[8
]}

Doucet, L. ^{[9
]}

Brosseau, S. ^{[10
]}

Wislez, M. ^{[1
,2
]}

Tredaniel, J. ^{[3
]}

Cadranel, J. ^{[1
,2
]}

机构：

[1] Hop Tenon, AP HP, 4 Rue Chine, F-75020 Paris, France

[2] Sorbonne Univ, 4 Rue Chine, F-75020 Paris, France

[3] Hop St Joseph, 185 Rue Raymond Losserand, F-75014 Paris, France

[4] Hop Foch, 40 Rue Worth, F-92151 Suresnes, France

[5] Ctr Hosp Intercommunal Creteil, 40 Ave Verdun, F-94000 Creteil, France

[6] Hop Avicenne, AP HP, 125 Rue Stalingrad, F-93000 Bobigny, France

[7] Hop Ambroise Pare, AP HP, 9 Ave Charles de Gaulle, F-92100 Boulogne, France

[8] Hop La Pitie Salpetriere, AP HP, 47-83 Blvd Hop, F-75013 Paris, France

[9] Hop St Louis, AP HP, 1 Ave Claude Vellefaux, F-75010 Paris, France

[10] Hop Bichat Claude Bernard, AP HP, 46 Rue Henri Huchard, F-75018 Paris, France

来源：

LUNG CANCER | 2019年 / 130卷

关键词：

Nivolumab; Non-small-cell lung cancer; Treatment; Refractory; DOCETAXEL; CHEMOTHERAPY;

D O I：

10.1016/j.lungcan.2019.01.015

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Introduction: : Immune checkpoint inhibitors (ICIs) have revolutionised cancer care especially in lung cancer. New response patterns have been described under ICIs such as pseudo-progression or hyper-progressive disease (HPD). The definition of HPD is yet to be consensual. The aim of this study was to suggest a clinical definition of nivolumab-refractory patients and find factors associated with this entity. Methods: : We performed a multi centric retrospective study including all patients who received nivolumab for the treatment of advanced non-small cell lung cancer (NSCLC) during the French authorisation for temporary use in 2015. Results: : 303 patients were included in the cohort and 292 had details on the number of nivolumab injections received. 57 patients (20%) were nivolumab-refractory. These patients had worse PS at nivolumab initiation (p < 0.0001), shorter duration of treatment before nivolumab (p = 0.028) and had dramatically shorter nivolumab overall survival (p < 0.0001) than patients who did not present with refractory disease. Conclusion: : Nivolumab-refractory disease can affect up to 20% of patients treated with nivolumab for advanced NSCLC with dramatically shortened survival rates. Further studies are needed to understand the precise mechanisms leading to refractory disease as well as its management.

引用

页码：128 / 134

页数：7

共 21 条

[1]

Arbour K. C., 2018, J CLIN ONCOL OFF J A, DOI [10.1200/JC0.2018.79.0006JCO2018790006, DOI 10.1200/JC0.2018.79.0006JCO2018790006]

[2] Bone specific immunity and its impact on metastasis [J].

Baschuk, Nikola ;

Rautela, Jay ;

Parker, Belinda S. .

BONEKEY REPORTS, 2015, 4

[3] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].

Borghaei, H. ;

Paz-Ares, L. ;

Horn, L. ;

Spigel, D. R. ;

Steins, M. ;

Ready, N. E. ;

Chow, L. Q. ;

Vokes, E. E. ;

Felip, E. ;

Holgado, E. ;

Barlesi, F. ;

Kohlhaeufl, M. ;

Arrieta, O. ;

Burgio, M. A. ;

Fayette, J. ;

Lena, H. ;

Poddubskaya, E. ;

Gerber, D. E. ;

Gettinger, S. N. ;

Rudin, C. M. ;

Rizvi, N. ;

Crino, L. ;

Blumenschein, G. R. ;

Antonia, S. J. ;

Dorange, C. ;

Harbison, C. T. ;

Finckenstein, F. Graf ;

Brahmer, J. R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639

[4] Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer [J].

Brahmer, Julie ;

Reckamp, Karen L. ;

Baas, Paul ;

Crino, Lucio ;

Eberhardt, Wilfried E. E. ;

Poddubskaya, Elena ;

Antonia, Scott ;

Pluzanski, Adam ;

Vokes, Everett E. ;

Holgado, Esther ;

Waterhouse, David ;

Ready, Neal ;

Gainor, Justin ;

Aren Frontera, Osvaldo ;

Havel, Libor ;

Steins, Martin ;

Garassino, Marina C. ;

Aerts, Joachim G. ;

Domine, Manuel ;

Paz-Ares, Luis ;

Reck, Martin ;

Baudelet, Christine ;

Harbison, Christopher T. ;

Lestini, Brian ;

Spigel, David R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (02) :123-135

[5] Hyperprogressive disease: recognizing a novel pattern to improve patient management [J].

Champiat, Stephane ;

Ferrara, Roberto ;

Massard, Christophe ;

Besse, Benjamin ;

Marabelle, Aurelien ;

Soria, Jean-Charles ;

Ferte, Charles .

NATURE REVIEWS CLINICAL ONCOLOGY, 2018, 15 (12) :748-762

[6] Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1 [J].

Champiat, Stephane ;

Dercle, Laurent ;

Ammari, Samy ;

Massard, Christophe ;

Hollebecque, Antoine ;

Postel-Vinay, Sophie ;

Chaput, Nathalie ;

Eggermont, Alexander ;

Marabelle, Aurelien ;

Soria, Jean-Charles ;

Ferte, Charles .

CLINICAL CANCER RESEARCH, 2017, 23 (08) :1920-1928

[7] Efficacy of next treatment received after nivolumab progression in patients with advanced nonsmall cell lung cancer [J].

Costantini, Adrien ;

Corny, Jennifer ;

Fallet, Vincent ;

Renet, Sophie ;

Friard, Sylvie ;

Chouaid, Christos ;

Duchemann, Boris ;

Giroux-Leprieur, Etienne ;

Taillade, Laurent ;

Doucet, Ludovic ;

Nguenang, Marina ;

Jouveshomme, Stephane ;

Wislez, Marie ;

Tredaniel, Jean ;

Cadranel, Jacques .

ERJ OPEN RESEARCH, 2018, 4 (02)

[8]

Ferrara R., 2018, JAMA ONCOL, DOI [10.1001/jamaonco1.2018, DOI 10.1001/JAMAONCO1.2018]

[9] Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer [J].

Gandhi, L. ;

Rodriguez-Abreu, D. ;

Gadgeel, S. ;

Esteban, E. ;

Felip, E. ;

De Angelis, F. ;

Domine, M. ;

Clingan, P. ;

Hochmair, M. J. ;

Powell, S. F. ;

Cheng, S. Y. -S. ;

Bischoff, H. G. ;

Peled, N. ;

Grossi, F. ;

Jennens, R. R. ;

Reck, M. ;

Hui, R. ;

Garon, E. B. ;

Boyer, M. ;

Rubio-Viqueira, B. ;

Novello, S. ;

Kurata, T. ;

Gray, J. E. ;

Vida, J. ;

Wei, Z. ;

Yang, J. ;

Raftopoulos, H. ;

Pietanza, M. C. ;

Garassino, M. C. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (22) :2078-2092

[10] Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden [J].

Hellmann, M. D. ;

Ciuleanu, T. -E. ;

Pluzanski, A. ;

Lee, J. S. ;

Otterson, G. A. ;

Audigier-Valette, C. ;

Minenza, E. ;

Linardou, H. ;

Burgers, S. ;

Salman, P. ;

Borghaei, H. ;

Ramalingam, S. S. ;

Brahmer, J. ;

Reck, M. ;

O'Byrne, K. J. ;

Geese, W. J. ;

Green, G. ;

Chang, H. ;

Szustakowski, J. ;

Bhagavatheeswaran, P. ;

Healey, D. ;

Fu, Y. ;

Nathan, F. ;

Paz-Ares, L. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (22) :2093-2104

← 1 2 3 →